Developed by our University against Covid-19 and supported by the Ministry of Health and Health Institutes of Turkey (TUSEB), TURCOVAC continues to be applied to the volunteers at ERU Medical Faculty Hospital within the scope of Phase-3 studies.
Turkey’s inactive Covid-19 vaccine, whose Phase-3 studies are ongoing, continues to be applied to the volunteers at ERU Medical Faculty Hospital.
In his statement to the journalists, Prof. Dr. Orhan Yıldız, Head of the Department of Infectious Diseases and Clinical Microbiology, gave information about the Phase-3 studies of TURCOVAC carried out at our university.
Mustafa Altuntaş, who volunteered for TURCOVAC within the scope of Phase-3 studies, stated that he was happy to contribute to the study and thanked Erciyes University for TURCOVAC.
Giving information about TURCOVAC in his speech, our Rector, Prof. Dr. Mustafa Çalış, said: “The Phase-3 studies of TURCOVAC vaccine, developed by our University and supported by TUSEB, continue. After the preclinical, Phase-1 and Phase-2 studies were completed at our university, we transferred the TURCOVAC vaccine to the Ministry of Health. Currently, Phase-3 studies have been continuing in Istanbul and Ankara under the coordination of the Ministry of Health. As of this week, the City Hospital and our university in Kayseri were included. Now, TURCOVAC Phase-3 studies are continuing in 5 centers. It is very important that Phase-1 and Phase-2 studies were carried out at our university, and it also matters that our university has been included in Phase-3 studies. We are proud of this. I hope Phase-3 studies will be completed quickly. We hope that TURCOVAC vaccine will be widely used with the approval of emergency use.”
Pointing out that the citizens showed great interest in TURCOVAC vaccine, Rector Çalış thanked the volunteers and said: “There are a great many volunteer applications via E-Nabiz and Phone number 0352 438 00 67. We would like to thank all volunteers in Phase 1, Phase-2 and Phase-3 studies.